J&J hits development roadblock with Crucell candidates
The company last year said it planned to submit three products for approval by the end of 2015--but now J&J says that timetable won't pan out. The products--FlumAb, a universal monoclonal antibody being studied to prevent influenza; FluCell, a cell-based flu vaccine; and a rabies antibody--came with J&J's buyout of Crucell. Last year, the company spent $2 billion for the part of the company it didn't already own; J&J had already acquired 18% of Crucell for $450 million.
The company did not specify a reason for the delay, The Wall Street Journal reports.
"We're still moving forward with them, and we haven't disclosed what the new filing dates may be," J&J spokeswoman Seema Kumar told the publication. "They just are not falling in the 2015 time frame."
J&J hoped the purchase of Crucell would give it a leg up in the vaccines business and a stronger hold in emerging markets. The company plans to work on both preventative and therapeutic vaccines.
- more from The Wall Street Journal
Crucell and Scripps find antibody for universal flu vax
WHO clears Crucell to put vax back on market
J&J/Crucell deal might snag on bid issues